z-logo
open-access-imgOpen Access
Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant action
Author(s) -
Kanzo Suzuki,
JiWoon Kim,
E. D. Nosyreva,
Ege T. Kavalali,
Lisa M. Monteggia
Publication year - 2021
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2021.109918
Subject(s) - antidepressant , neuroscience , nmda receptor , pharmacology , hippocampus , ampa receptor , signal transduction , glutamatergic , biology , glutamate receptor , chemistry , receptor , microbiology and biotechnology , biochemistry
SUMMARY Ketamine is a noncompetitive glutamatergic N -methyl- d -aspartate receptor (NMDAR) antagonist that exerts rapid antidepressant effects. Preclinical studies identify eukaryotic elongation factor 2 kinase (eEF2K) signaling as essential for the rapid antidepressant action of ketamine. Here, we combine genetic, electrophysiological, and pharmacological strategies to investigate the role of eEF2K in synaptic function and find that acute, but not chronic, inhibition of eEF2K activity induces rapid synaptic scaling in the hippocampus. Retinoic acid (RA) signaling also elicits a similar form of rapid synaptic scaling in the hippocampus, which we observe is independent of eEF2K functioni. The RA signaling pathway is not required for ketamine-mediated antidepressant action; however, direct activation of the retinoic acid receptor α (RARα) evokes rapid antidepressant action resembling ketamine. Our findings show that ketamine and RARα activation independently elicit a similar form of multiplicative synaptic scaling that is causal for rapid antidepressant action.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom